ZA201202168B - Formulations comprising triptan compounds - Google Patents

Formulations comprising triptan compounds

Info

Publication number
ZA201202168B
ZA201202168B ZA2012/02168A ZA201202168A ZA201202168B ZA 201202168 B ZA201202168 B ZA 201202168B ZA 2012/02168 A ZA2012/02168 A ZA 2012/02168A ZA 201202168 A ZA201202168 A ZA 201202168A ZA 201202168 B ZA201202168 B ZA 201202168B
Authority
ZA
South Africa
Prior art keywords
formulations
triptan compounds
triptan
compounds
Prior art date
Application number
ZA2012/02168A
Inventor
Rajesh Gandhi
Arun Jana
Sreekanth Manikonda
Sameer Shrinivas Kunte
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2010/001708 external-priority patent/WO2011036521A2/en
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of ZA201202168B publication Critical patent/ZA201202168B/en

Links

ZA2012/02168A 2009-09-25 2012-03-23 Formulations comprising triptan compounds ZA201202168B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN2337CH2009 2009-09-25
IN2607CH2009 2009-10-27
US29221310P 2010-01-05 2010-01-05
US29220610P 2010-01-05 2010-01-05
PCT/IB2010/001708 WO2011036521A2 (en) 2009-09-25 2010-06-17 Formulations comprising triptan compounds

Publications (1)

Publication Number Publication Date
ZA201202168B true ZA201202168B (en) 2012-12-27

Family

ID=47647712

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/02168A ZA201202168B (en) 2009-09-25 2012-03-23 Formulations comprising triptan compounds

Country Status (4)

Country Link
JP (1) JP5845183B2 (en)
CN (1) CN102933198B (en)
ES (1) ES2553862T3 (en)
ZA (1) ZA201202168B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6478695B2 (en) * 2015-02-20 2019-03-06 株式会社マンダム Evaluation method of test substance and hypoosmotic stimulation inhibitor
JP6941224B2 (en) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー Intranasal epinephrine preparations and methods for the treatment of the disease
CN117503704A (en) * 2023-11-09 2024-02-06 广州新济药业科技有限公司 Nasal spray acting on central nervous system and preparation method and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3455297A (en) * 1996-07-11 1998-02-09 Farmarc Nederland Bv Pharmaceutical composition containing acid addition salt of basic drug
WO2006025882A2 (en) * 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US20090136505A1 (en) * 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
WO2006091722A2 (en) * 2005-02-23 2006-08-31 Uab Research Foundation Alkyl-glycoside enhanced vaccination
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth

Also Published As

Publication number Publication date
CN102933198A (en) 2013-02-13
JP5845183B2 (en) 2016-01-20
CN102933198B (en) 2015-10-07
JP2013505924A (en) 2013-02-21
ES2553862T3 (en) 2015-12-14

Similar Documents

Publication Publication Date Title
ZA201106050B (en) Dye-polymers formulations
GB0815435D0 (en) Formulations
EP2393493A4 (en) Compounds
EP2491025A4 (en) Azaazulene compounds
GB2459691B (en) Formulations
GB0823269D0 (en) Formulations
IL269369A (en) Improved formulations
GB0821789D0 (en) Formulations
GB0919210D0 (en) Formulations
EP2307021A4 (en) Formulations
AP2909A (en) Pyrazinoisoquinoline Compounds
ZA201202168B (en) Formulations comprising triptan compounds
EP2443115A4 (en) Compounds
IL217390A0 (en) Formulations
GB0921378D0 (en) Formulations
GB0916030D0 (en) Formulations
GB0822171D0 (en) Temisartan formulations
GB0914489D0 (en) Improved formulations
GB0823486D0 (en) Formulations
GB0817079D0 (en) Formulations
GB0823493D0 (en) Formulations
GB0807906D0 (en) Formulations
GB0916106D0 (en) Formulations
GB0811447D0 (en) Formulations
GB0816876D0 (en) Formulations